New Delhi, April 1 Marksans Pharma Ltd announced on Wednesday that it has received final approval from the US health regulator for its generic version of Benzonatate capsules, indicated for the treatment of persistent cough, bronchitis, pneumonia, or other lung infections.
The approval from the US Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Benzonatate capsules of strengths 100 mg and 200 mg, Marksans Pharma said in a regulatory filing.
This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc, it added.
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia, or other lung infections, the company said.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.